Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Highlights:
• Incannex have engaged Curia to scale up cGMP fill-finish manufacture of IHL-216A
• Engagement of Curia follows achievement of “proof-of-concept” formulation development
• A patent has been filed on the composition of IHL-216A
• The first cGMP batch of IHL-216A manufactured at Curia will be used in a phase 1 clinical trial
• Incannex is targeting a pre-IND meeting with FDA in Q3 2022 to discuss the most efficient clinical trial development plan to achieve commercialisation for IHL-216A.